New HIV Prevention Shot Shows 100% Efficacy in Women

Lenacapavir injections, administered twice a year, offer a promising alternative to daily HIV prevention pills.

Clinical trials in South Africa and Uganda demonstrated total protection against HIV in over 5,000 women and girls.
Lenacapavir is already FDA-approved for HIV treatment but not yet for prevention.
Researchers emphasize the need for affordable pricing to ensure global access, particularly in low-income countries.
The drug's manufacturer, Gilead, faces pressure to license the drug for cheaper generic production.
Further studies are ongoing to assess the drug's efficacy in other high-risk groups, including men.